179 related articles for article (PubMed ID: 37963940)
1. SETD5 regulates the OGT-catalyzed O-GlcNAcylation of RNA polymerase II, which is involved in the stemness of colorectal cancer cells.
Cho HI; Jo S; Kim MS; Kim HB; Liu X; Xuan Y; Cho JW; Jang YK
Sci Rep; 2023 Nov; 13(1):19885. PubMed ID: 37963940
[TBL] [Abstract][Full Text] [Related]
2. Human RNA Polymerase II Promoter Recruitment in Vitro Is Regulated by O-Linked N-Acetylglucosaminyltransferase (OGT).
Lewis BA; Burlingame AL; Myers SA
J Biol Chem; 2016 Jul; 291(27):14056-14061. PubMed ID: 27129214
[TBL] [Abstract][Full Text] [Related]
3. Distributive O-GlcNAcylation on the Highly Repetitive C-Terminal Domain of RNA Polymerase II.
Lu L; Fan D; Hu CW; Worth M; Ma ZX; Jiang J
Biochemistry; 2016 Feb; 55(7):1149-58. PubMed ID: 26807597
[TBL] [Abstract][Full Text] [Related]
4. O-GlcNAcylation promotes colorectal cancer progression by regulating protein stability and potential catcinogenic function of DDX5.
Wu N; Jiang M; Han Y; Liu H; Chu Y; Liu H; Cao J; Hou Q; Zhao Y; Xu B; Xie X
J Cell Mol Med; 2019 Feb; 23(2):1354-1362. PubMed ID: 30484950
[TBL] [Abstract][Full Text] [Related]
5. SET Domain-Containing Protein 5 Enhances the Cell Stemness of Non-Small Cell Lung Cancer via the PI3K/Akt/mTOR Pathway.
Chen Q; Sun Z; Li J; Zhang D; Guo B; Zhang T
J Environ Pathol Toxicol Oncol; 2021; 40(2):55-63. PubMed ID: 33822517
[TBL] [Abstract][Full Text] [Related]
6. mTOR/MYC Axis Regulates O-GlcNAc Transferase Expression and O-GlcNAcylation in Breast Cancer.
Sodi VL; Khaku S; Krutilina R; Schwab LP; Vocadlo DJ; Seagroves TN; Reginato MJ
Mol Cancer Res; 2015 May; 13(5):923-33. PubMed ID: 25636967
[TBL] [Abstract][Full Text] [Related]
7. O-GlcNAc transferase activates stem-like cell potential in hepatocarcinoma through O-GlcNAcylation of eukaryotic initiation factor 4E.
Cao B; Duan M; Xing Y; Liu C; Yang F; Li Y; Yang T; Wei Y; Gao Q; Jiang J
J Cell Mol Med; 2019 Apr; 23(4):2384-2398. PubMed ID: 30677218
[TBL] [Abstract][Full Text] [Related]
8. Potential role of O-GlcNAcylation and involvement of PI3K/Akt1 pathway in the expression of oncogenic phenotypes of gastric cancer cells in vitro.
Zhang N; Chen X
Biotechnol Appl Biochem; 2016 Nov; 63(6):841-851. PubMed ID: 26333304
[TBL] [Abstract][Full Text] [Related]
9. Feedback Regulation of
Lin CH; Liao CC; Chen MY; Chou TY
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33801653
[TBL] [Abstract][Full Text] [Related]
10. Evidence of the involvement of O-GlcNAc-modified human RNA polymerase II CTD in transcription in vitro and in vivo.
Ranuncolo SM; Ghosh S; Hanover JA; Hart GW; Lewis BA
J Biol Chem; 2012 Jul; 287(28):23549-61. PubMed ID: 22605332
[TBL] [Abstract][Full Text] [Related]
11. Fine-tuning the cardiac O-GlcNAcylation regulatory enzymes governs the functional and structural phenotype of the diabetic heart.
Prakoso D; Lim SY; Erickson JR; Wallace RS; Lees JG; Tate M; Kiriazis H; Donner DG; Henstridge DC; Davey JR; Qian H; Deo M; Parry LJ; Davidoff AJ; Gregorevic P; Chatham JC; De Blasio MJ; Ritchie RH
Cardiovasc Res; 2022 Jan; 118(1):212-225. PubMed ID: 33576380
[TBL] [Abstract][Full Text] [Related]
12. O-GlcNAcylation-inducing treatments inhibit estrogen receptor α expression and confer resistance to 4-OH-tamoxifen in human breast cancer-derived MCF-7 cells.
Kanwal S; Fardini Y; Pagesy P; N'tumba-Byn T; Pierre-Eugène C; Masson E; Hampe C; Issad T
PLoS One; 2013; 8(7):e69150. PubMed ID: 23935944
[TBL] [Abstract][Full Text] [Related]
13. Decreasing O-GlcNAcylation affects the malignant transformation of MCF-7 cells via Hsp27 expression and its O-GlcNAc modification.
Netsirisawan P; Chaiyawat P; Chokchaichamnankit D; Lirdprapamongkol K; Srisomsap C; Svasti J; Champattanachai V
Oncol Rep; 2018 Oct; 40(4):2193-2205. PubMed ID: 30106436
[TBL] [Abstract][Full Text] [Related]
14.
Xu Z; Isaji T; Fukuda T; Wang Y; Gu J
J Biol Chem; 2019 Mar; 294(9):3117-3124. PubMed ID: 30587575
[No Abstract] [Full Text] [Related]
15. Histone methyltransferase Dot1L recruits O-GlcNAc transferase to target chromatin sites to regulate histone O-GlcNAcylation.
Xu B; Zhang C; Jiang A; Zhang X; Liang F; Wang X; Li D; Liu C; Liu X; Xia J; Li Y; Wang Y; Yang Z; Chen J; Zhou Y; Chen L; Sun H
J Biol Chem; 2022 Jul; 298(7):102115. PubMed ID: 35690146
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of SETD5 Inhibits Colorectal Cancer Cell Growth and Stemness by Regulating PI3K/AKT/mTOR Pathway.
Zhou X; Chen W; Zhuang D; Xu G; Puyang Y; Rui H
Biochem Genet; 2024 Apr; ():. PubMed ID: 38641699
[TBL] [Abstract][Full Text] [Related]
17. O-GlcNAcylation modulates HBV replication through regulating cellular autophagy at multiple levels.
Wang X; Lin Y; Liu S; Zhu Y; Lu K; Broering R; Lu M
FASEB J; 2020 Nov; 34(11):14473-14489. PubMed ID: 32892442
[TBL] [Abstract][Full Text] [Related]
18. Aβ-affected pathogenic induction of S-nitrosylation of OGT and identification of Cys-NO linkage triplet.
Ryu IH; Lee KY; Do SI
Biochim Biophys Acta; 2016 May; 1864(5):609-21. PubMed ID: 26854602
[TBL] [Abstract][Full Text] [Related]
19. SET domain-containing 5 is a potential prognostic biomarker that promotes esophageal squamous cell carcinoma stemness.
Piao L; Li H; Feng Y; Yang Z; Kim S; Xuan Y
Exp Cell Res; 2020 Apr; 389(1):111861. PubMed ID: 31981592
[TBL] [Abstract][Full Text] [Related]
20. O-GlcNAc transferase is involved in glucocorticoid receptor-mediated transrepression.
Li MD; Ruan HB; Singh JP; Zhao L; Zhao T; Azarhoush S; Wu J; Evans RM; Yang X
J Biol Chem; 2012 Apr; 287(16):12904-12. PubMed ID: 22371499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
